Significant benefit seen in Phase III trial of experimental drug for kidney disease


The clinical trial of an experimental drug for patients with chronic kidney disease showed significant reduction in albuminuria for 50% of participants. Combining the drug with standard-care medication led to 70% of participants experiencing significant reduction in albuminuria. This experimental drug, designed to inhibit aldosterone production, reduced the negative effects of ACE inhibitors and ARBs, while also preventing dangerous side effects. These results have prompted a Phase III clinical trial, leading researchers to believe these findings could eliminate the need for dialysis for patients with diabetes or hypertensive kidney disease. The study was published in The Lancet, with Dr. Katherine Tuttle as lead author.

Source link

error: Content is protected !!